Global Custom Market Research Reports Provider Company

phone

Pulmonary Arterial Hypertension - Pipeline Review, H2 2018

  • Published Date: 07 Aug 2018
  • Number of Pages: 269
  • Category: Pharmaceuticals
  • Country: Global
Pulmonary Arterial Hypertension - Pipeline Review, H2 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H2 2018, provides an overview of the Pulmonary Arterial Hypertension (Cardiovascular) pipeline landscape.

Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids and calcium channel blockers.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 9, 11, 20, 35, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 4 molecules, respectively.

Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pulmonary Arterial Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct


Introduction 5
Pulmonary Arterial Hypertension - Overview 6
Pulmonary Arterial Hypertension - Therapeutics Development 7
Pulmonary Arterial Hypertension - Therapeutics Assessment 20
Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development 32
Pulmonary Arterial Hypertension - Drug Profiles 55
Pulmonary Arterial Hypertension - Dormant Projects 244
Pulmonary Arterial Hypertension - Discontinued Products 247
Pulmonary Arterial Hypertension - Product Development Milestones 248
Appendix 259

List Of Tables

List of Tables
Number of Products under Development for Pulmonary Arterial Hypertension, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Acceleron Pharma Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Actelion Pharmaceuticals Ltd, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Aerogen Ltd, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Arena Pharmaceuticals Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Ascendis Pharma A/S, H2 2018
Pulmonary Arterial Hypertension - Pipeline by AVEO Pharmaceuticals Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Bayer AG, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Bial - Portela & Ca SA, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Biogen Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Bristol-Myers Squibb Co, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Camurus AB, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Capricor Therapeutics Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Celsion Corp, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Celtaxsys Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Chiesi Farmaceutici SpA, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Complexa Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Denovo Biopharma LLC, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Eli Lilly and Co, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Gilead Sciences Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by GlaxoSmithKline Plc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Insmed Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Insys Therapeutics Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Japan Tobacco Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Johnson & Johnson, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Liquidia Technologies Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by MannKind Corp, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Mezzion Pharma Co Ltd, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Nippon Shinyaku Co Ltd, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Nissan Chemical Industries Ltd, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Northern Therapeutics Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Novartis AG, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Peloton Therapeutics Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Pulmokine Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Reata Pharmaceuticals Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Relief Therapeutics Holding AG, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Respira Therapeutics Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Reviva Pharmaceuticals Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Roivant Sciences Ltd, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Serodus ASA, H2 2018
Pulmonary Arterial Hypertension - Pipeline by SteadyMed Therapeutics Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Suda Pharmaceuticals Ltd, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Toray Industries Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by United Therapeutics Corp, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Vicore Pharma AB, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Vivus Inc, H2 2018
Pulmonary Arterial Hypertension - Dormant Projects, H2 2018
Pulmonary Arterial Hypertension - Discontinued Products, H2 2018

List Of Figures

List of Figures
Number of Products under Development for Pulmonary Arterial Hypertension, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2018 T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - CD28 is a proteins expressed on T

View Report

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H2 2018 Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4

View Report

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Pipeline Review, H2 2018 Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) pipeline Target

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports